Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more
Solvonis Therapeutics plc (SVNS) - Net Assets
Latest net assets as of June 2025: GBX6.93 Million GBX
Based on the latest financial reports, Solvonis Therapeutics plc (SVNS) has net assets worth GBX6.93 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.54 Million) and total liabilities (GBX2.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX6.93 Million |
| % of Total Assets | 72.66% |
| Annual Growth Rate | 0.7% |
| 5-Year Change | 100.0% |
| 10-Year Change | N/A |
| Growth Volatility | 170.66 |
Solvonis Therapeutics plc - Net Assets Trend (2018–2024)
This chart illustrates how Solvonis Therapeutics plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Solvonis Therapeutics plc (2018–2024)
The table below shows the annual net assets of Solvonis Therapeutics plc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX3.08 Million | +52.22% |
| 2023-12-31 | GBX2.03 Million | -55.51% |
| 2022-12-31 | GBX4.55 Million | +460.84% |
| 2021-12-31 | GBX812.00K | -47.34% |
| 2021-05-31 | GBX1.54 Million | -9.45% |
| 2020-05-31 | GBX1.70 Million | -24.04% |
| 2019-05-31 | GBX2.24 Million | -23.87% |
| 2018-05-31 | GBX2.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solvonis Therapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1006100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX2.23 Million | 72.41% |
| Other Components | GBX11.41 Million | 369.84% |
| Total Equity | GBX3.08 Million | 100.00% |
Solvonis Therapeutics plc Competitors by Market Cap
The table below lists competitors of Solvonis Therapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crown Place VCT PLC
LSE:CRWN
|
$0.33 |
|
BRIDGEFORT CAPITAL LIMITED CLASS B
XZIM:BFCB
|
$0.38 |
|
WILLDALE LIMITED
XZIM:WILD
|
$0.43 |
|
STAR AFRICA CORPORATION LIMITED
XZIM:SACL
|
$0.50 |
|
BRIDGEFORT CAPITAL LIMITED
XZIM:BFCA
|
$0.22 |
|
PYX Resources Limited
LSE:PYX
|
$0.21 |
|
SigmaBroadband Co
PINK:SGRB
|
$0.12 |
|
Seneca Growth Capital VCT PLC
LSE:HYG
|
$0.08 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solvonis Therapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,026,000 to 3,084,000, a change of 1,058,000 (52.2%).
- Net loss of 1,590,000 reduced equity.
- Other comprehensive income decreased equity by 3,949,000.
- Other factors increased equity by 6,597,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.59 Million | -51.56% |
| Other Comprehensive Income | GBX-3.95 Million | -128.05% |
| Other Changes | GBX6.60 Million | +213.91% |
| Total Change | GBX- | 52.22% |
Book Value vs Market Value Analysis
This analysis compares Solvonis Therapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 91.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 8.66x to 91.89x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-05-31 | GBX0.03 | GBX0.25 | x |
| 2019-05-31 | GBX0.02 | GBX0.25 | x |
| 2020-05-31 | GBX0.02 | GBX0.25 | x |
| 2021-05-31 | GBX0.01 | GBX0.25 | x |
| 2021-12-31 | GBX0.01 | GBX0.25 | x |
| 2022-12-31 | GBX0.04 | GBX0.25 | x |
| 2023-12-31 | GBX0.02 | GBX0.25 | x |
| 2024-12-31 | GBX0.00 | GBX0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solvonis Therapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-51.56%) is above the historical average (-59.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -16.77% | 0.00% | 0.00x | 1.05x | GBX-788.50K |
| 2019 | -31.36% | -2424.14% | 0.01x | 1.23x | GBX-927.20K |
| 2020 | -31.59% | -163.03% | 0.13x | 1.52x | GBX-708.30K |
| 2021 | -17.79% | -39.70% | 0.25x | 1.79x | GBX-428.49K |
| 2021 | -117.49% | -435.62% | 0.07x | 3.85x | GBX-1.04 Million |
| 2022 | -59.40% | -499.08% | 0.11x | 1.08x | GBX-3.16 Million |
| 2023 | -154.00% | -531.52% | 0.24x | 1.20x | GBX-3.32 Million |
| 2024 | -51.56% | 0.00% | 0.00x | 1.04x | GBX-1.90 Million |
Industry Comparison
This section compares Solvonis Therapeutics plc's net assets metrics with peer companies in the Specialty Industrial Machinery industry.
Industry Context
- Industry: Specialty Industrial Machinery
- Average net assets among peers: $24,395,346
- Average return on equity (ROE) among peers: 0.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solvonis Therapeutics plc (SVNS) | GBX6.93 Million | -16.77% | 0.38x | $0.27 |
| Avingtrans Plc (AVG) | $69.29 Million | 3.62% | 0.76x | $23.48K |
| Castings PLC (CGS) | $73.23 Million | 10.43% | 0.28x | $13.94K |
| Clean Power Hydrogen PLC (CPH2) | $-37.00K | 0.00% | 0.00x | $2.75K |
| EQTEC plc (EQT) | $1.36 Million | 0.00% | 6.90x | $3.91 Million |
| Goodwin PLC (GDWN) | $29.49 Million | 29.77% | 1.79x | $179.22K |
| Graft Polymer UK PLC (GPL) | $1.54 Million | -17.79% | 0.79x | $460.92 |
| ITM Power (ITM) | $347.00K | -171.47% | 0.56x | $47.95K |
| MPAC Group PLC (MPAC) | $61.83 Million | 9.19% | 0.85x | $13.26K |
| PowerHouse Energy Group Plc (PHE) | $-100.60K | 0.00% | 0.00x | $2.45K |
| Renold (RNO) | $7.00 Million | 145.71% | 27.23x | $19.97K |